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WHODAS 2.0 in prodromal Huntington disease:
measures of functioning in neuropsychiatric disease
Nancy R Downing1,6, Ji-In Kim2,6, Janet K Williams1, Jeffrey D Long2,3, James A Mills2, Jane S Paulsen*,2,4,5
and The PREDICT-HD Investigators and Coordinators of the Huntington Study Group
Clinical trials to improve day-to-day function in Huntington disease (HD) require accurate outcome measures. The DSM-5
recommends the World Health Organization Disability Assessment Schedule (WHODAS) 2.0 for use in neuropsychiatric
disorders. The DSM-5 also states proxy measures may be useful when cognitive function may be impaired. We tested WHODAS
participant and companion ratings for differences in baseline and longitudinal function in three prodromal HD groups and a
control group. Participants with prodromal HD were stratified by disease progression (low, medium, and high disease burden)
based on their cytosine–adenine–guanine (CAG)-age product (CAP) score. Participant (N¼726) and companion (N¼630)
WHODAS scores were examined for group differences, and for participant versus companion differences using linear mixed
effects regression and Akaike’s information criterion to test model fit. We also compared WHODAS with the Total Functional
Capacity (TFC) scale. At baseline, functioning on the WHODAS was rated worse by participants in the high group and
companions compared with controls. For longitudinal changes, companions reported functional decline over time in the medium
and high groups. In simultaneous analysis, participant and companion longitudinal trajectories showed divergence in the high
group, suggesting reduced validity of self-report. The WHODAS showed greater longitudinal difference than the TFC in the
medium group relative to controls, whereas the TFC showed greater longitudinal difference than WHODAS in the high group.
Results suggest the WHODAS can identify baseline and longitudinal differences in prodromal HD and may be useful in HD
clinical trials. Companions may provide more accurate data as the disease progresses.
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INTRODUCTION
Huntington disease (HD) is an autosomal-dominant inherited
neurodegenerative condition caused by a cytosine–adenine–guanine
(CAG) expansion in the HTT gene.1 Although HD diagnosis is based
on motor signs, the disease is accompanied by cognitive and
functional decline and behavioral and psychiatric disturbances that
progress to severe functional impairment, dementia, and premature
death.2 These changes can be detected up to 15 years before motor
diagnosis,3 a period referred to as prodromal HD. The changes
associated with HD progression have the potential to impact day-to-
day function.4–7
The World Health Organization defines function as the impact of
interactions between health conditions, environmental and personal
factors on daily activities, participation in society, and bodily
functions of an individual.8 The Food and Drug Administration
identified day-to-day function as an important outcome variable to
include in patient-related outcome measures for use in clinical trials.9
This emphasizes that treatments for health conditions should result in
subjective improvements of daily functioning.
Measures to detect changes in function in prodromal HD are
needed for use in clinical trials of treatments to delay or prevent
symptoms associated with HD.10 Previous publications using
traditional measures of daily functioning in HD have suggested
that current measures are insensitive to very early changes and as a
result fail to document more subtle alterations in functioning that
accompany early cognitive, motor, and behavioral changes due to
disease.6–11 The Total Functional Capacity (TFC) scale12 is
recommended by the National Institute of Neurological
Disorders and Stroke as a core measure of functional capacity in
research with participants with HD.13 However, clinical trials based
on this measure may lack sensitivity for the detection of early
functional disturbances.6 The fifth edition of the Diagnostic and
Statistical Manual for Mental Disorders has abolished the multi-
axial system and recommended that the World Health
Organization Disability Assessment Schedule (WHODAS) 2.0 be
used to provide a measure of daily functioning and disability in
neuropsychiatric disorders. Rationale for the deletion of the
previous measure, the Global Assessment of Functioning scale,
was secondary to its lack of conceptual clarity and questionable
psychometrics in routine practice. On the dawn of the DSM-5, the
field is challenged to provide data with which to understand and
interpret this newly recommended scale. An objective of the
current study was to administer the WHODAS to a large group
of people with prodromal HD who, by definition, reflect the
1College of Nursing, University of Iowa, Iowa City, IA, USA; 2Department of Psychiatry, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA, USA;
3Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, IA, USA; 4Department of Neurology, Roy J. and Lucille A. Carver College of Medicine,
University of Iowa, Iowa City, IA, USA; 5Department of Psychology, University of Iowa, Iowa City, IA, USA
*Correspondence: Dr JS Paulsen, Department of Psychiatry, Psychiatry Research, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, 1-305 Medical Education
Building, Iowa City 52242-1000, IA, USA. Tel: +319 353 4551; Fax: +319 353 3003; E-mail: predict-publications@uiowa.edu
6These are the co first-authors.
Received 7 August 2013; revised 18 September 2013; accepted 10 October 2013; published online 11 December 2013
European Journal of Human Genetics (2014) 22, 958–963
& 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14
www.nature.com/ejhg
progression of neuropsychiatric disease from mild to moderate and
to present the findings as a benchmark for other disorders.
The 36-item WHODAS measures day-to-day functioning across
health conditions. In contrast to the TFC’s global assessment of
function, the WHODAS assesses specific areas of cognitive, beha-
vioral, and physical functioning. The WHODAS has not previously
been used in an HD sample and one purpose of this research was to
compare the WHODAS with the traditional functional capacity
measure used in HD, the TFC scale.
The DSM-5 also recommends administration of the proxy WHO-
DAS when patients have impaired cognitive capacity. There is
evidence of impaired awareness of cognitive, behavioral, and motor
changes in people with HD before diagnosis.14 Therefore, it may be
critical to understand the validity of self-report (versus proxy-report)
of outcome measures considered for clinical trials in HD. The aims of
the study were (1) to examine cross-sectional and longitudinal
participant- and companion-rated measures of daily activity using
the 36-item WHODAS in groups of individuals with varying degrees
of prodromal disease progression and gene non-expanded controls;
(2) to compare longitudinal participant and companion ratings on
the WHODAS, and (3) to compare the WHODAS and the TFC in
terms of baseline and longitudinal differences.
MATERIALS AND METHODS
Participants
Participants were from the Neurobiological Predictors of HD (PREDICT-HD)
study. Participants independently underwent testing for the HD gene mutation
and knew their gene status before study participation. Individuals with the
CAG repeat expansion (CAG Z36) served as cases, whereas people at risk for
HD who tested negative for the gene expansion (CAGo36) served as controls.
The PREDICT-HD study began data collection in 2001 and the WHODAS was
added to the battery in 2009. The TFC was collected in its entirety from 2001
to 2008 and then an abbreviated TFC was collected based on an item-by-item
analysis of existing data.
The analysis used data from 726 participants with 1413 observations and
630 companions with 1117 observations. Companions were predominately
spouse/partner (74%) followed by friend/neighbor (8%), parent (7%), and
sibling (5%), and 74.6% of the companions reported living with the
participants. The mean number of years knowing the participant was 20.77
(SD¼ 13.59) years. The median number of follow-up visits was 2 (range¼
1–4), and the length of follow-up was up to 3.11 years (median¼ 1.14 years).
We analyzed data from participants who were currently employed outside their
home or attending school. Eight percent of observations (not subjects) were
omitted because of missing data.
Progression groups
Individuals entered PREDICT-HD with different disease progression levels and
were classified accordingly. Baseline refers to the initial visit when the
WHODAS was first administered for each participant. Participants were
classified into one of three prodromal HD groups based on their CAG-Age
Product (CAP) score,15 computed as CAP¼ (age at baseline) (CAG–33.66).
The CAP formula was derived from a parametric accelerated failure time
model predicting motor diagnosis from age at entry, CAG length, and their
interaction. CAP is similar to the ‘disease burden’ score of Penny et al.16 and is
presumed to index the cumulative toxicity of mutant huntingtin at the time of
study entry. CAP can be converted to a scaled version expressing the 5-year
probability of motor diagnosis from study entry (5 years is roughly the average
time to diagnosis for the converters in PREDICT-HD). Cutoffs were derived
for the best fitting subgroups based on an optimization algorithm using an
earlier sample of PREDICT-HD participants.15 Based on gene status and a
discretization of the CAP distribution, four groups were defined in this
analysis: control, low, medium, and high. The estimated time to motor
diagnosis for each CAP group is412.8 years for the low group, 7.6–12.8 years
for the medium group, and o7.6 years for the high group.
Measures
The WHODAS includes 36 items in six areas of day-to-day functioning:
understanding and communicating (6 items); getting around (5 items); self-
care (4 items); getting along with others (5 items); activities at home, work,
and/or school (8 items); and participation in society (8 items). There are five
response categories for each item (none¼ 1; mild¼ 2; moderate¼ 3;
severe¼ 4; extreme/cannot do¼ 5). The range of scores for the WHODAS is
36–180 with higher scores indicating worse functioning. For participants, the
WHODAS was administered by a trained staff member. For companions, the
WHODAS was administered by a trained staff member or was self-adminis-
tered. All respondents were asked to rate how much difficulty the participant
had with each item and how much these difficulties interfered with the
participant’s life.
The TFC consists of five questions related to the functioning domains of
occupation, finances, domestic chores, activities of daily living, and care level.
Each item has either three or four response categories (0 to either 2 or 3) for a
total possible range of scores from 0 to 13, with higher scores indicating better
functioning. The TFC is rated by a clinician following a 5- to 10-min narrative
interview with each participant and their companion together. Rating choices
are specific to each functional domain (eg, usual level, full capacity, impaired).
In PREDICT-HD 2.0, only two TFC items, occupation and finance, were
collected because of a need to reduce the functional battery. The three omitted
items were endorsed by fewer than 2% of participants in PREDICT-HD 1.0.6
The retained two items were summed to yield a modified TFC score in this
analysis, with a range of 0–6. To facilitate comparison with the WHODAS, TFC
was scaled as TFC loss, so that high scores indicate worse function. Thus,
results are reported as TFC loss computed as 6–(occupation item scoreþ
finance item score). TFC loss scores ranged from 0 to 6 with higher score
indicating worse functioning.
Statistical methods
The WHODAS total score was calculated as the sum of the 36-item scores
according to the simple scoring and missing data instructions.17 Baseline
characteristics were compared by group using an analysis of variance for
continuous variables and a w2 test for categorical variables. To examine the
internal consistency of the WHODAS and TFC, Cronbach’s alpha analyses
were performed using baseline WHODAS and modified TFC scores.
Group comparison
To examine group differences in baseline status and rate of change over time,
participant and companion ratings were analyzed separately using linear mixed
effects regression (LMER).18 The time metric duration was time since initial
WHODAS administration expressed in years. All models included gender,
years of education, and age at entry as covariates. Three models were fitted to
test for baseline (intercept) and longitudinal (slope) group differences: Model 1
was a null model that included the covariates and duration as predictors, but
no group differences; Model 2 added group main effects to examine baseline
differences among the groups (baseline effect); Model 3 added the interaction
between duration and groups to test differences in the rate of change among
the groups (longitudinal effect). Details are provided in Supplementary
Appendix A.1.
The models were evaluated using Akaike’s information criterion (AIC),
corrected for small-sample bias (AICc).19,20 Two scalings of AICc were used:
the difference in AICc (dAICc) and the AICc weight (wAICc). The dAICc was
computed as the difference in AICc values between each model and the model
with the lowest AICc with smaller values indicating better fit (the best fitting
model would have dAICc¼ 0 and all other models dAICc 40). The wAICc
was a probability scaling (0rwAICcr1), with values closer to one indicating
better fit. If Model 2 or 3 was the best fitting, baseline and longitudinal
differences between controls and each gene-expanded group were reported.
Participant and companion comparison
To test whether participant and companion slopes were equal in each group,
participant and companion data were modeled simultaneously using multi-
response LMER. Details are provided in Supplementary Appendix A.2. There
were various combinations of equal and non-equal slopes among the groups
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resulting in 16 possible candidate models as shown in the appendices
(Supplementary Appendix Table A.2). Model 1 was the simplest having equal
slopes in all groups, and Model 16 was the most complex having unequal
slopes in all groups. All models included gender, years of education, and age at
entry as covariates. The models were assessed by AICc values as described
above to examine which groups had statistically reliable slope differences. The
relative importance of the slope discrepancy of each group was assessed by the
sum of the weights (wAICc) across all models with unequal group slopes (eight
models for each group).21 A sum closer to one indicates higher importance.
Fitted curves were drawn using model-averaged parameters over all models.21
WHODAS and TFC comparison
The relative sensitivity of the WHODAS ratings was evaluated by comparison
to the TFC. Because TFC loss and WHODAS had different units, both were
transformed to a common scale by subtracting the mean and then dividing by
the standard deviation. For each scaled measure, the model with baseline and
longitudinal group differences was fitted. The effect sizes were based on the
baseline and longitudinal differences between the controls and each of the
gene-expanded groups. The effect sizes were the t-values of the differences
computed as the difference divided by its standard error. In each group, effect
sizes were compared between WHODAS and TFC when the effect was
significant for at least one measure.
All statistical analyses were performed in R 2.15.2 and LMER analyses were
performed using the package lme4.22,23
RESULTS
Group comparison
Participant characteristics at initial WHODAS administration are
presented in Table 1. Cronbach’s alpha values were 0.92 for
participant WHODAS, 0.91 for companion WHODAS, and 0.87 for
modified TFC indicating a relatively high of degree of internal consistency.
Table 2 displays the model comparisons for participants and
companions (analyzed separately). For participants, the model with
baseline differences among groups was best fitting (wAICc¼ 0.80). In
contrast, the model with both baseline and longitudinal differences
among groups was the best fitting for companions (wAICc¼ 0.95).
For the two best fitting models, all the parameter estimates are
presented in the Supplementary Appendix Table A.1.
Table 3 lists the group comparison WHODAS results for the best
fitting models from Table 2. For each effect, the focus was on the
difference between the controls and each of the gene-expanded groups
for self-reported functioning. The upper portion of Table 3 presents
baseline group differences for participants. The baseline difference
relative to controls increased going from low to high. The difference
for the high group was positive and significant (Po0.001). This
indicates that self-reported functioning at baseline was significantly
worse for the high group than controls. The difference for the
medium group was marginally significant (P¼ 0.054).
The bottom portion of Table 3 presents both baseline and long-
itudinal group differences for companion-rated functioning of
participants. Similar to the participant results, the baseline difference
relative to controls increased from low to high. The baseline difference
for the high group was positive and significant (Po0.001), indicating
companions of participants in the high group reported significantly
worse participant functioning at baseline than companions of the
controls. Unlike the baseline difference, the longitudinal difference
relative to controls did not have a monotonic change with group. For
the longitudinal difference, the medium and high group differences
were positive and significant (all P¼ 0.02), indicating companions of
persons in these groups reported significantly worse functioning of
participants over time relative to companions of the controls.
Participant and companion comparison
The simultaneous analysis of participant and companion WHODAS
scores addressed whether longitudinal changes of participant and
companion ratings were different in each group. Figure 1 shows the
fitted curves using model-averaged coefficients across all models. The
participant and companion curves were relatively similar in each
group from the control to the medium group indicating similar rates
of change over time in participant and companion ratings.
In contrast, there was a divergence between the two curves in the
high group indicating companions reported worse functional decline
over time than participants. The divergence in the high group was
much more reliable than the other groups as indicated by the sum of
weights shown in the Supplementary Appendix Table A.3
(high group weight¼ 0.93). It was notable that in the medium group
Table 1 Participant characteristics at initial WHODAS administration
Control Low Med High Group comparison
N 223 127 174 202
N of companions 198 112 148 172
Sex (% male) 37 33 40 45 w2(3)¼5.33 (P¼0.15)
Age (years)
Mean 47 35.1 42.2 47.5 F(3,722)¼45.25 (Po0.001)
SD 11.7 10.1 10.2 9.9
Education (years)
Mean 15 14.6 14.9 14.5 F(3,722)¼1.46 (P¼0.22)
SD 2.5 2.3 2.3 2.8
WHODAS
Mean 40.1 40.4 41.9 43.4 F(3,722)¼4.22 (P¼0.0057)
SD 8.7 8.3 10.8 12
Companion WHODAS
Mean 39.3 40.4 41 43.2 F(3,626)¼5.07 (P¼0.0018)
SD 6.6 7.4 8.9 10.5
Modified TFC a
Mean 5.9 6.0 5.9 5.8 F(3,722)¼3.48 (P¼0.016)
SD 0.4 0.2 0.5 0.6
Abbreviations: Med, medium; TFC, Total Functional Capacity; WHODAS, World Health
Organization Disability Assessment Schedule.
aModified TFC¼ occupation item scoreþ finances item score, occupation (0¼ unable,
1¼marginal work only, 2¼ reduced capacity for usual job, 3¼normal), finances (0¼unable,
1¼major assistance, 2¼ slight assistance, 3¼ normal).
Table 2 Separate participant and companion WHODAS analysis
results
Variable Model Group effect AICc dAICc wAICc
Participant 1 Null 3603.69 14.23 0.00
2 Baseline 3589.46 0.00 0.80
3 Baselineþ longitudinal 3592.18 2.72 0.20
Companion 1 Null 2890.19 22.50 0.00
2 Baseline 2873.56 5.87 0.05
3 Baselineþ longitudinal 2867.68 0.00 0.95
Abbreviations: AICc, Akaike’s information criterion corrected for small-sample bias; dAICc,
difference in AICc; wAICc, AICc weight; WHODAS, World Health Organization Disability
Assessment Schedule.
The models with smallest AICc values are the best models and are displayed in boldface type.
Models with wAICc closest to 1.0 indicate the best fit and are displayed in boldface type.
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the slope increased sharply for both participants and companions
indicating much faster functional decline over time rated by
participants and companions.
WHODAS and TFC comparison
Companion WHODAS ratings were better at detecting baseline and
longitudinal group differences than participant ratings. Therefore,
comparison was made between companion WHODAS and TFC.
At baseline, 93% of participants had the minimum possible TFC loss
and 38% of companion-rated participants had the minimum possible
WHODAS. For participants with repeated measures, only 10% had a
change in TFC loss over time. In contrast, 75% had a WHODAS
rating that changed over time.
We also focused on the baseline and longitudinal differences
between the controls and each of the gene-expanded groups. Group
comparison results for the companion WHODAS and TFC loss scores
are shown in the Supplementary Appendix Table A.4. At baseline,
companion WHODAS had a larger difference than TFC loss for the
high group (t¼ 3.80 versus 2.33). There was no significant baseline
difference for the low and medium groups. For the longitudinal
differences, companion WHODAS ratings had a larger difference for
the medium group (t¼ 2.33 versus 1.93), whereas TFC loss had a
larger difference for the high group (t¼ 3.76 versus 2.3). There were
no significant longitudinal differences for the low group. Figure 2
shows fitted curves for the companion WHODAS and TFC loss. The
baseline differences relative to controls were larger in all groups for
companion WHODAS than TFC loss. The longitudinal difference for
the medium group was larger for companion WHODAS, whereas the
longitudinal difference for the high group was larger for TFC loss.
DISCUSSION
This is the first known analysis of the WHODAS 2.0 in prodromal
HD. The aims of this study were to examine baseline and longitudinal
changes in participant and companion ratings of the WHODAS, to
compare participant and companion ratings of function in prodromal
HD, and compare the ability of the TFC and the WHODAS to detect
baseline and longitudinal functional changes.
The participant and companion WHODAS baseline differences
increased relative to controls from low to high groups, indicating that
stratification based on CAP scores facilitates identification of cross-
sectional differences in day-to-day functioning that may be obscured
if prodromal participants are compared with controls without
Figure 1 Fitted LMER curves by group for participant and companion WHODAS ratings. All model coefficients were estimated adjusting for gender, age at
baseline, and years of education. The plots show the WHODAS total score as a function of duration, informant (participant or companion), and group.
Table 3 Comparison of WHODAS scores between control group and each of the gene expanded groups for the best fitting models from Table 2
Difference with control
Measure (best model) Effect Groups Estimate SE t-value P-value
Participant Baseline Low 0.32 1.12 0.28 0.78
(baseline group effect model) Med 1.89 0.98 1.94 0.054 þ
High 3.99 0.93 4.28 o0.001 ***
Companion Baseline Low 1.54 1.13 1.37 0.17
(baselineþ longitudinal Med 1.58 0.99 1.59 0.11
group effect model) High 3.71 0.98 3.80 o0.001 ***
Longitudinal Low 0.72 0.97 0.74 0.46
Med 2.09 0.90 2.33 0.020 *
High 1.95 0.85 2.30 0.022 *
Abbreviations: Med, medium; WHODAS, World Health Organization Disability Assessment Schedule.
***Po0.001, **Po0.01, *Po0.05, þPo0.1.
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stratification. The ability to identify differences in baseline function-
ing by estimated proximity to motor diagnosis may be useful for
establishing inclusion criteria in clinical trials.
The main finding of the participant and companion comparison is
the significant divergence in participant and companion WHODAS
scores by progression group. Participant and companion ratings were
concordant in the control, low, and medium groups with both
participants and companions reporting declines in functioning over
time. The decline in the medium group was sharp, indicating that
impairment in day-to-day functioning became most noticeable to
both participants and companions 7.6–12.8 years before motor
diagnosis. It may be optimal to begin interventions that target
preservation of day-to-day functioning in the medium group.
In the high group, there is a divergence between participant and
companion reports with participants reporting slower rate of func-
tional decline than companions, who report decline at a rate similar
to the medium group with greater functional loss. These results
suggest that proxy measures may be more reliable in detecting day-to-
day functional changes in later stages of prodromal HD disease
progression. The Food and Drug Administration advocates the use of
patient-related outcome measures to evaluate treatment benefit with
data coming directly from the patient.9 However, the discrepancy
between participant and companion reports in the high group may
indicate declining self-awareness of functional changes because of
frontal-subcortical dysfunction that occurs in HD. Awareness of loss-
of-functional abilities is impaired in diagnosed HD.24 It is unclear at
what point lack of awareness begins in the HD disease process,
although awareness of executive dysfunction has been shown to be
impaired before motor diagnosis.14 Our results support proxy data
may be more helpful than participant data in measuring day-to-day
functional decline in participants nearing motor diagnosis.
Measures that show evidence of sensitivity to change over time are
crucial for use in clinical trials to delay or prevent symptoms of HD.
It has been challenging to find measures that detect functional
changes in people estimated to be relatively far from motor
diagnosis.25 We compared the ability of the TFC and the
companion WHODAS to detect functional changes in prodromal
HD. The TFC showed more functional loss in the high group than the
companion WHODAS. The WHODAS showed more functional loss
in the medium group than the TFC and was also able to detect
changes in the high group, although the effect size was not as great as
the TFC for the high group. Even so, the WHODAS detected greater
variability of change over time across all prodromal groups than the
TFC. A majority of companion WHODAS ratings (75%) showed
longitudinal changes, whereas only a minority of TFC ratings (10%)
showed longitudinal changes. Baseline variability was also greater in
the WHODAS (38% with best possible score versus 93% for the TFC).
Therefore, the WHODAS has greater sensitivity in detecting change
over time in prodromal HD than the TFC.
This study presents WHODAS 2.0 data from the largest sample of
prodromal HD participants to date. A limitation of this study is that
we relied on only two items from the TFC, which somewhat reduced
the variability of the outcome. Although the omitted items were
endorsed by fewer than 2% of participants in PREDICT-HD 1.0,6
their potential impact on the variability of the TFC in our sample is
unknown. Also, we used LMER modeling in our analysis, which may
not be appropriate for change over time in the TFC considering its
limited variability. There is no TFC companion measure although
companions may be present during the clinician-led interview that is
conducted to complete the TFC. Companions may be reluctant to
report functional impairments with participants present. It is possible
a companion TFC may be useful in detecting functional changes in
the medium group. The companion WHODAS was not administered
in a consistent manner, with some being administered by trained staff,
and others self-administered. We have not analyzed results for
differences related to method of administration. However, in both
methods, the participant was not present during administration.
The findings from this study support the WHODAS 2.0 is better at
detecting changes in day-to-day functioning in earlier stages of
prodromal HD than the TFC and is an index of HD disease
progression. The WHODAS may be more useful than the TFC to
test the ability of treatments and interventions to preserve day-to-day
functioning at this stage of disease progression. Treatments should
ideally begin before striatal volume loss, which declines precipitously
15 years before motor diagnosis.3 Measures that are sensitive to
functional changes further out from motor diagnosis are critical for
use in clinical trials. The WHODAS is sensitive to change in groups
estimated to be 12.8 years and less from motor diagnosis.
The companion WHODAS performed better than the participant
version in the longitudinal analysis and there was a discrepancy in
reporting of function between participants and companions in the
high group. Owing to the concern for lack of awareness of functional
impairment in prodromal HD, it is important to consider including
companion measures of day-to-day function in studies designed to
test the effectiveness of treatments and interventions to improve
functional outcomes. Our findings suggest the WHODAS may be
useful in other neuropsychiatric diseases, which supports the DSM-5
recommendation.
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